Abstract CT103: Final results for OptimalTTF-1: Optimizing Tumor Treating Fields with targeted skull remodeling surgery for first recurrence glioblastoma: Phase 1 trial: In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA):

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisKonferenceabstrakt i tidsskriftForskningpeer review

We present a clinical open label, phase-1 trial (OptimalTTF-1, NCT02893137), which aims to test a novel treatment for first recurrence glioblastoma (rGBM). The aim of the treatment is to optimize the electric field generated by Tumor Treating Fields (TTFields) with targeted and individualized skull-remodeling surgery (SR-surgery). Selectively placed burrholes reduces the electric resistance created by the bone and thus improves the electric field focally. Preclinical research has indicated this conclusion. The final analysis examined the toxicity and efficacy of this combined intervention in addition to best practice chemotherapy.
OriginalsprogEngelsk
ArtikelnummerCT103
TidsskriftCancer Research
Vol/bind80
Nummer16, suppl.
ISSN0008-5472
DOI
StatusUdgivet - 2020
BegivenhedAACR Annual Meeting 2020 - Philadelphia, USA
Varighed: 27 apr. 202028 apr. 2020

Konference

KonferenceAACR Annual Meeting 2020
LandUSA
ByPhiladelphia
Periode27/04/202028/04/2020

Se relationer på Aarhus Universitet Citationsformater

ID: 195927358